Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pergamum AB Announces a Strategic Collaboration with Cadila Pharmaceuticals

Published: Monday, February 11, 2013
Last Updated: Sunday, February 10, 2013
Bookmark and Share
Both Companies will collaborate on the preclinical and clinical development of a novel therapeutic peptide.

Pergamum AB and Cadila Pharmaceuticals Ltd have announced a strategic collaboration to develop a novel treatment of infections with a unique targeting mechanism clearly distinguished from classical antibiotics.

Pergamum is part of the Karolinska Development portfolio.

The two companies will collaborate on the preclinical and clinical development of a novel therapeutic peptide that has been developed by Pergamum AB.

The development will be conducted at the facilities of Cadila Pharmaceuticals Ltd in Ahmedabad, India.

Cadila will be responsible for all costs related to the development of the product up to Phase II and global rights will be shared between the companies.

Infections caused by resistant microorganisms often fail to respond to conventional treatment, resulting in prolonged illness and greater risk of death. There is a significant need for safe and effective new products to avoid infections.

"Pergamum has developed a new class of short synthetic peptides with both anti-infective and anti-inflammatory properties derived from the body’s own defense system. There is a rapidly increasing global prevalence of antibiotics resistance that limits the therapeutic value of conventional products, and we think that we can meet this need with this novel therapeutic peptide”, says Jonas Ekblom, CEO of Pergamum.

"This partnership combines Cadila’s advanced product development capabilities with the innovative capacity of Pergamum. Cadila Pharmaceuticals bring their expertise in drug development and demonstrates that commitment towards developing affordable innovative compounds to the market in this collaboration”, says Rajiv Modi, Chairman and Managing Director of Cadila Pharmaceuticals Ltd.

"We are delighted to see this collaboration between Cadila and Pergamum. This is a phenomenal opportunity for Pergamum to work with one of the largest pharmaceutical companies in India, a key emerging pharmaceutical market. The strategic value can be substantial for both parties”, commented Torbjörn Bjerke, CEO of Karolinska Development AB and Chairman of Pergamum AB.

The establishment of this cooperation was facilitated by Dr. CB Sanjeevi of Karolinska Institutet and Business Sweden.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Karolinska Development Appoints New Chief Financial Officer
Christian Tange will start working with Karolinska Development from February 1, 2014.
Thursday, January 30, 2014
NovaSAID Initiates Partnership with Cadila Pharmaceuticals
Strategic partnership to develop innovative treatments in inflammation and pain management.
Friday, January 10, 2014
EU Research Grants Awarded to Three of Karolinska Development’s Portfolio Companies
Goal is to develop new ways to treat infectious diseases.
Monday, December 30, 2013
Karolinska Development Invests in Forendo Pharma
The stepwise funding commitments are expected to reach EUR 10m over a period of three years, of which Karolinska Development will invest up to EUR 3.0m.
Wednesday, June 26, 2013
Athera and Boehringer Ingelheim Enter Into an Option Agreement
Agreement on a novel therapy for atherosclerosis.
Friday, June 21, 2013
EU Grants EUR 6m to Athera´s Cardiovascular Disease Antibody Therapy
EUR 6m grant has been provided to the CARDIMMUN consortium.
Monday, June 17, 2013
Dilaforette - Phase II Study with Sevuparin for the Treatment of Severe Malaria Initiated
Company gets approval from the regulatory authority to start Phase II trial in India.
Thursday, May 16, 2013
Preliminary Results of a Phase II Study Indicates that Axelar’s AXL1717 is Effective in treating NSCLC Patients
Axelar to finalize the trial with approximately 100 patients.
Monday, April 08, 2013
Aprea Announces Positive Data from a Clinical Phase I/II Study with APR-246
Results from the study have been published in the Journal of Clinical Oncology.
Wednesday, September 19, 2012
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!